Stocks & Investing
Stocks and Investing
Stocks and Investing
Mon, November 14, 2022
[ Mon, Nov 14th 2022
] - WOPRAI
[ Mon, Nov 14th 2022
] - WOPRAI
[ Mon, Nov 14th 2022
] - WOPRAI
[ Mon, Nov 14th 2022
] - WOPRAI
[ Mon, Nov 14th 2022
] - WOPRAI
[ Mon, Nov 14th 2022
] - WOPRAI
[ Mon, Nov 14th 2022
] - WOPRAI
[ Mon, Nov 14th 2022
] - WOPRAI
[ Mon, Nov 14th 2022
] - WOPRAI
[ Mon, Nov 14th 2022
] - WOPRAI
[ Mon, Nov 14th 2022
] - WOPRAI
[ Mon, Nov 14th 2022
] - WOPRAI
[ Mon, Nov 14th 2022
] - WOPRAI
[ Mon, Nov 14th 2022
] - WOPRAI
[ Mon, Nov 14th 2022
] - WOPRAI
[ Mon, Nov 14th 2022
] - WOPRAI
[ Mon, Nov 14th 2022
] - WOPRAI
[ Mon, Nov 14th 2022
] - WOPRAI
[ Mon, Nov 14th 2022
] - WOPRAI
[ Mon, Nov 14th 2022
] - WOPRAI
[ Mon, Nov 14th 2022
] - WOPRAI
[ Mon, Nov 14th 2022
] - WOPRAI
[ Mon, Nov 14th 2022
] - WOPRAI
[ Mon, Nov 14th 2022
] - WOPRAI
[ Mon, Nov 14th 2022
] - WOPRAI
[ Mon, Nov 14th 2022
] - WOPRAI
[ Mon, Nov 14th 2022
] - WOPRAI
Chris Schott Downgraded (TEVA) to Sell and Decreased Target to $10 on, Nov 14th, 2022
Chris Schott of JP Morgan, Downgraded "Teva Pharmaceutical Industries Limited" (TEVA) to Sell and Decreased Target from $11 to $10 on, Nov 14th, 2022.
Chris has made no other calls on TEVA in the last 4 months.
There are 4 other peers that have a rating on TEVA. Out of the 4 peers that are also analyzing TEVA, 2 agree with Chris's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Gary Nachman of "BMO Capital" Maintained at Hold with Decreased Target to $10 on, Monday, November 7th, 2022
- Nathan Rich of "Goldman Sachs" Maintained at Hold with Increased Target to $10 on, Tuesday, August 2nd, 2022
These are the ratings of the 2 analyists that currently disagree with Chris
- Glen Santangelo of "Jefferies" Initiated at Strong Buy and Held Target at $10 on, Friday, October 21st, 2022
- Jason Gerberry of "B of A Securities" Upgraded from Hold to Strong Buy and Increased Target to $13 on, Friday, August 5th, 2022
